Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival (Q34688195)

3 August 2017

1 reference

title

Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival (English)

1 reference

3 August 2017

0 references

1 reference

Jennifer Nishioka

1

1 reference

3 August 2017

Susan Goodin

series ordinal

2

1 reference

3 August 2017

publication date

1 June 2007

1 reference

Journal of Oncology Pharmacy Practice

3 August 2017

published in

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

85-97

1 reference

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Dalteparin Compared with an Oral Anticoagulant for Thromboprophylaxis in Patients with Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

21 January 2018

The heparins and cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

The effect of low molecular weight heparin on survival in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207079169

21 January 2018

Identifiers

DOI

10.1177/1078155207079169

1 reference

3 August 2017

1 reference